These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 10888786)
1. Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Wynn SS; Nagabundi S; Koo J; Chin NW Arch Pathol Lab Med; 2000 Jul; 124(7):1074-6. PubMed ID: 10888786 [TBL] [Abstract][Full Text] [Related]
2. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists. Mohanty SK; Lobo A; Williamson SR; Shah RB; Trpkov K; Varma M; Sirohi D; Aron M; Kandukari SR; Balzer BL; Luthringer DL; Ro J; Osunkoya AO; Desai S; Menon S; Nigam LK; Sardana R; Roy P; Kaushal S; Midha D; Swain M; Ambekar A; Mitra S; Rao V; Soni S; Jain K; Diwaker P; Pattnaik N; Sharma S; Chakrabarti I; Sable M; Jain E; Jain D; Samra S; Vankalakunti M; Mohanty S; Parwani AV; Sancheti S; Kumari N; Jha S; Dixit M; Malik V; Arora S; Munjal G; Gopalan A; Magi-Galluzzi C; Dhillon J Int J Surg Pathol; 2023 Sep; 31(6):993-1005. PubMed ID: 35946087 [No Abstract] [Full Text] [Related]
3. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation. Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167 [TBL] [Abstract][Full Text] [Related]
4. [Serum chromogranin A in prostate cancer]. Akakura K Nihon Rinsho; 2002 Dec; 60 Suppl 11():160-4. PubMed ID: 12599564 [No Abstract] [Full Text] [Related]
6. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358 [TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064 [TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329 [TBL] [Abstract][Full Text] [Related]
9. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569 [TBL] [Abstract][Full Text] [Related]
10. A case of synchronous double primary lung cancer with neuroendocrine features. Niho S; Yokose T; Nagai K; Nishiwaki Y; Kodama T; Mukai K Jpn J Clin Oncol; 1999 Apr; 29(4):219-25. PubMed ID: 10340047 [TBL] [Abstract][Full Text] [Related]
11. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237 [TBL] [Abstract][Full Text] [Related]
12. A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy. Ladwa R; Gustafson S; McCaffrey E; Miles K; O'Byrne K Clin Nucl Med; 2017 Jun; 42(6):e311-e312. PubMed ID: 28240670 [TBL] [Abstract][Full Text] [Related]
13. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Cussenot O; Villette JM; Cochand-Priollet B; Berthon P Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663 [TBL] [Abstract][Full Text] [Related]
14. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cox ME; Deeble PD; Lakhani S; Parsons SJ Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer metastatic to the omentum. Kehinde EO; Abdeen SM; Al-Hunayan A; Ali Y Scand J Urol Nephrol; 2002; 36(3):225-7. PubMed ID: 12201941 [TBL] [Abstract][Full Text] [Related]
16. Prostatic ductal adenocarcinoma showing Bcl-2 expression. Tulunay O; Orhan D; Baltaci S; Gögüş C; Müftüoglu YZ Int J Urol; 2004 Sep; 11(9):805-8. PubMed ID: 15379952 [TBL] [Abstract][Full Text] [Related]
17. [Large bowel obstruction due to colonic and omental metastasis as the first clinical sign of metastatic ductal carcinoma of the breast]. Bognár G; Barabás L; Diczházi C; Ondrejka P Magy Seb; 2009 Oct; 62(5):312-5. PubMed ID: 19828422 [TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. di Sant'Agnese PA Cancer; 1992 Jul; 70(1 Suppl):254-68. PubMed ID: 1350941 [TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. McWilliam LJ; Manson C; George NJ Br J Urol; 1997 Aug; 80(2):287-90. PubMed ID: 9284204 [TBL] [Abstract][Full Text] [Related]
20. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review. Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]